PMC5733174_01
Right eye pre- and posttreatment fundus images, FFA and OCT scans. (a) Pretreatment color fundus image showing PED with CNVM. (b) and (c) Pretreatment FFA with 2 PEDs (asterix) and CNVM (white arrow). (d) Posttreatment color fundus image showing scarred CNVM with flattened PEDs. (e) and (f) Posttreatment FFA showing scarred CNVM with no leakage. (g) Pretreatment OCT demonstrating submacular CNVM complex (broad arrow with white borders), SRF (yellow arrow), and PED (narrow white arrow). (h) Posttreatment OCT demonstrating regressed CNVM complex (broad arrow with white borders), resolved SRF (yellow arrow), and reduced PED height (narrow white arrow).
CRIOPM2017-5036248.001.jpg
PMC5733174_01_CRIOPM2017-5036248.001.jpg
fig1
There was a large partially scarred grayish yellow submacular membrane of about 1 disc diameter in size with small streak of subretinal hemorrhage suggestive of Choroidal Neovascular Membrane (CNVM) (Figure 1(a)). Fundus Fluorescein Angiography (FFA) in OD revealed features of classic CNVM with a scarred component (Figures 1(b) and 1(c)). OCT, Carl Zeiss Meditec AG, Germany) was done using Raster line scanning protocol. OD revealed a blunted foveal contour, cystoid changes in the macula along with a shallow layer of SRF, and submacular CNVM complex (Figure 1(g)).
Left eye pre- and posttreatment fundus images, FFA and OCT scans. (a) Pretreatment color fundus image showing RPE alterations over papilla-macular bundle. (b) and (c) Pretreatment FFA with transmission defects and ink blot hyperfluorescence (white circle). (d) Posttreatment color fundus image showing RPE alterations suggestive of resolved CSCR. (e) and (f) Posttreatment FFA showing healed CSCR with no leakage (yellow circle).
CRIOPM2017-5036248.002.jpg
PMC5733174_01_CRIOPM2017-5036248.002.jpg
fig2
There were subtle retinal pigment epithelium (RPE) alterations over the papilla-macular bundle (PMB) (Figure 2(a)). FFA in OS revealed transmission window defects over the papilla-macular bundle and superonasally (Figures 2(b) and 2(c)).